Thioridazine lacks bactericidal activity in an animal model of extracellular tuberculosis

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 6, 2013, Pages 1327-1330

  Dutta, Noton K ^a   Pinn, Michael L ^a   Zhao, Ming ^a   Rudek, Michelle A ^a   Karakousis, Petros C ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Chemotherapy; Guinea pigs; Isoniazid; Mycobacterium tuberculosis; Phenothiazine; Toxicity

Indexed keywords

ISONIAZID; THIORIDAZINE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; DRUG TOLERABILITY; EXPERIMENTAL GUINEA PIG; FEMALE; HISTOLOGY; LUNG BURDEN; LUNG GRANULOMA; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SINGLE DRUG DOSE; TREATMENT RESPONSE; WEIGHT REDUCTION;

CHEMOTHERAPY; GUINEA PIGS; ISONIAZID; MYCOBACTERIUM TUBERCULOSIS; PHENOTHIAZINE; TOXICITY;

AEROSOLS; ANIMALS; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDPOINT DETERMINATION; EXTRACELLULAR SPACE; FEMALE; GUINEA PIGS; HUMANS; MICE; MYCOBACTERIUM TUBERCULOSIS; ORGAN SIZE; THIORIDAZINE; TUBERCULOSIS;

EID: 84880288729     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt037     Document Type: Article

References (21)

1. Dutta NK, Karakousis PC. Tuberculosis chemotherapy: present situation, possible solutions, and progress towards a TB-free world. Indian J Med Microbiol 2012; 30: 261-3.
2. Ordway D, Viveiros M, Leandro Cet al. Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 917-22.
3. Viveiros M, Amaral L. Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines. Int J Antimicrob Agents 2001; 17: 225-8.
4. Dutta NK, Mazumdar K, Dastidar SG et al. New patentable use of an old neuroleptic compound thioridazine to combat tuberculosis: a gene regulation perspective. Recent Pat Antiinfect Drug Discov 2011; 6: 128-38.
5. Dutta NK, Mehra S, Kaushal D. A Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine. PLoS One 2010; 5: e10069.
6. Abbate E, Vescovo M, NatielloMet al. Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine. J Antimicrob Chemother 2012; 67: 473-7.
7. Amaral L, Udwadia Z, Abbate E et al. The added effect of thioridazine in the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2012; 16: 1706-8.
8. Ahmad Z, Fraig MM, Bisson GP et al. Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. Antimicrob Agents Chemother 2011; 55: 1527-32.
9. Ahmad Z, Klinkenberg LG, Pinn ML et al. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J infect Dis 2009; 200: 1136-43.
10. Ahmad Z, Nuermberger EL, Tasneen R et al. Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. J Antimicrob Chemother 2010; 65: 729-34.
11. Dutta NK, Illei PB, Peloquin CA et al. Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. Antimicrob Agents Chemother 2012; 56: 3726-31.
12. Chakraborty BS, Midha KK, McKay G et al. Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study. J Pharm Sci 1989; 78: 796-801.
13. McMurray DN. Disease model: pulmonary tuberculosis. Trends Mol Med 2001; 7: 135-7.
14. Vandiviere HM, Loring WE, Melvin I et al. The treated pulmonary lesion and its tubercle bacillus. II. The death and resurrection. Am J Med Sci 1956; 232: 30-7.
15. Lenaerts AJ, Hoff D, Aly S et al. Location of persisting mycobacteria in a guinea pig model of tuberculosis revealed by R207910. Antimicrob Agents Chemother 2007; 51: 3338-45.
16. Haapanen JH, Kass I, Gensini G et al. Studies on the gaseous content of tuberculous cavities. Am Rev Respir Dis 1959; 80: 1-5.
17. Thanacoody RH. Thioridazine: the good and the bad. Recent Pat Antiinfect Drug Discov 2011; 6: 92-8.
18. Martins M, Viveiros M, Kristiansen JE et al. The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In Vivo 2007; 21: 771-5.
19. van Soolingen D, Hernandez-Pando R, Orozco H et al. The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS One 2010; 5: e12640.
20. Nyberg G, Martensson E. Binding of thioridazine and thioridazine metabolites to serum proteins. An in vitro study. Naunyn Schmiedebergs Arch Pharmacol 1982; 319: 189-96.
21. Rosenthal IM, Tasneen R, Peloquin CA et al. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother 2012; 56: 4331-40.